Rafael Holdings reports Q3 net loss of $1.5M; invests $2.1M in Cyclo Therapeutics

Rafael Holdings, Inc.

2023-Q3 EPS reported -$0.14 revenue$211,000

Net loss from continuing operations $1.5M ($0.06/sh) vs $5.0M ($0.25/sh) year ago.
Cash, equivalents and marketable securities $82.4M as of April 30, 2023.
Made initial $2.1M investment in Cyclo Therapeutics and agreement to invest additional $5M.
R&D expenses fell to $0.7M from $1.4M on winding down early-stage programs.
General and administrative expenses $2.3M for Q3, including $0.6M stock-based comp.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Rafael Holdings, Inc. reported the third quarter of fiscal 2023 for the three months ended April 30, 2023 results: net income net loss from continuing operations of $1.5 million, or $0.06 per share, EPS $0.06 per share.

Period: the third quarter of fiscal 2023 for the three months ended April 30, 2023
Net income: net loss from continuing operations of $1.5 million, or $0.06 per share
EPS: $0.06 per share
Result: reported results

Exact text from the filing

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

View on SEC.gov

310 earnings releases filed in the last 30 days. Browse all earnings releases →

Rafael Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-048570

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.